ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
IL-13 dysregulation plays a critical role in the pathogenesis of a variety of inflammatory and remodeling diseases. In these settings, STAT6 is believed to be the canonical signaling molecule mediating the tissue effects of IL-13. Signaling cascades involving MAPKs have been linked to inflammation and remodeling. We hypothesized that MAPKs play critical roles in effector responses induced by IL-13 in the lung. We found that Tg IL-13 expression in the lung led to potent activation of ERK1/2 but not JNK1/2 or p38. ERK1/2 activation also occurred in mice with null mutations of STAT6. Systemic administration of the MAPK/ERK kinase 1 (MEK1) inhibitor PD98059 or use of Tg mice in which a dominant-negative MEK1 construct was expressed inhibited IL-13-induced inflammation and alveolar remodeling. There were associated decreases in IL-13-induced chemokines (MIP-1alpha/CCL-3, MIP-1beta/CCL-4, MIP-2/CXCL-1, RANTES/CCL-5), MMP-2, -9, -12, and -14, and cathepsin B and increased levels of alpha1-antitrypsin. IL-13-induced tissue and molecular responses were noted that were equally and differentially dependent on ERK1/2 and STAT6 signaling. Thus, ERK1/2 is activated by IL-13 in the lung in a STAT6-independent manner where it contributes to IL-13-induced inflammation and remodeling and is required for optimal IL-13 stimulation of specific chemokines and proteases as well as the inhibition of specific antiproteases. ERK1/2 regulators may be useful in the treatment of IL-13-induced diseases and disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IL-4 receptor: signaling mechanisms and biologic functions
Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.701 · Cited by 1,545
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Self-citationChiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603
IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK
Moore, P. E., Church, T. L., Chism, D. D., Panettieri, R. A., & Shore, S. A. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00245.2001 · Cited by 166
Cited by
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Mebratu, Y., & Tesfaigzi, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8147 · Cited by 957
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Pathobiology of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease
Yoshida, T., & Tuder, R. M. (2007) · Physiological Reviews · doi:10.1152/physrev.00048.2006 · Cited by 510
Animal models of chronic obstructive pulmonary disease
Wright, J. L., Cosio, M., & Churg, A. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90200.2008 · Cited by 447
Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2
He, C. H., Lee, C. G., Dela Cruz, C. S., Lee, C.-M., Zhou, Y., Ahangari, F., Ma, B., Herzog, E. L., Rosenberg, S. A., Li, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.032 · Cited by 326
IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies
Ingram, J. L., & Kraft, M. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.034 · Cited by 253
Toll-like receptor 4 deficiency causes pulmonary emphysema
Zhang, X., Shan, P., Jiang, G., Cohn, L., & Lee, P. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28139 · Cited by 221
“morphometric chord length assessments as previously described (73).”
MethodSelf-citationLiu, W., Liang, Q., Balzar, S., Wenzel, S., Gorska, M., & Alam, R. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.004 · Cited by 126
Singh, S. P., Gundavarapu, S., Peña-Philippides, J. C., Rir-sima-ah, J., Mishra, N. C., Wilder, J. A., Langley, R. J., Smith, K. R., & Sopori, M. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101567 · Cited by 93
“2/MAPK pathway, independent of STAT6 (68, 69), STAT6 also controls Th2 cytokines and goblet cell metaplasia (70).”
BackgroundTargeting the MEK1 Cascade in Lung Epithelium Inhibits Proliferation and Fibrogenesis by Asbestos
Manning, C. B., Sabo-Attwood, T., Robledo, R. F., MacPherson, M. B., Rincón, M., Vacek, P., Hemenway, D., Taatjes, D. J., Lee, P. J., & Mossman, B. T. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0382oc · Cited by 20
“The fact that epithelial cell and lung remodeling are altered after inhibition of the MEK1 pathway in asbestos-exposed mice is consistent with our recent observation that dnMEK1 Tg1 mice crossed with IL-13–overexpressing mice show inhibition of IL13–induced inflammation and alveolar remodeling as measured by decreases…”
Background
Metadata
- Authors
- Lee, P. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-12-08
- Volume
- 116
- Issue
- 1
- Pages
- 163-173
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2064282998
- Cited by
- 123
- References
- 4
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.